Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.49 |
| ▸ | MAOA | P21397 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radezolid SCHEMBL1035776 | 0.93 | MAOA (0.56) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL30061945 | 0.93 | MAOA (0.56) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL3165892 | 0.93 | MAOA (0.56) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL2723587 | 0.93 | MAOA (0.55) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL15633880 | 0.93 | MAOA (0.55) | CALML3MAOACYP3A4CYP2C19MAOB | |
| SCHEMBL12181349 | 0.91 | CALML3 (0.51) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL15634976 | 0.91 | MAOA (0.53) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL15634852 | 0.91 | MAOA (0.53) | CALML3MAOACYP3A4CYP2C19MAOB | |
| Radezolid SCHEMBL15634749 | 0.89 | MAOA (0.52) | CALML3MAOACYP3A4CYP2C19MAOB | |
| SCHEMBL1035788 | 0.89 | CALML3 (0.48) | CALML3MAOACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2024-07-16 | — | — | US | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2016-03-03 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | CALML3 4426/4885MAOA 1726/4885CYP3A4 14/4885 |
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | NCEH1, NRDC, LPL | CALML3 4061/4885MAOA 1440/4885CYP3A4 2310/4885 |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | NCEH1, NRDC, LPL | CALML3 4061/4885MAOA 1440/4885CYP3A4 2310/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | CALML3 4339/4885MAOA 1794/4885CYP3A4 22/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | CALML3 4426/4885MAOA 1726/4885CYP3A4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.